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Abstract
Background Lifestyle therapy with resistance training is a potent measure to counteract age-related loss in muscle strength
and mass. Unfortunately, many individuals fail to respond in the expected manner. This phenomenon is particularly common
among older adults and those with chronic diseases (e.g. chronic obstructive pulmonary disease, COPD) and may involve en-
docrine variables such as vitamin D. At present, the effects of vitamin D supplementation on responses to resistance training
remain largely unexplored.
Methods Ninety-five male and female participants (healthy, n = 71; COPD, n = 24; age 68 ± 5 years) were randomly assigned
to receive either vitamin D3 or placebo supplementation for 28 weeks in a double-blinded manner (latitude 61°N, September–
May). Seventy-eight participants completed the RCT, which was initiated by 12 weeks of supplementation-only (two weeks
with 10 000 IU/day, followed by 2000 IU/day), followed by 13 weeks of combined supplementation (2000 IU/day) and super-
vised whole-body resistance training (twice weekly), interspersed with testing and measurements. Outcome measures in-
cluded multiple assessments of muscle strength (nvariables = 7), endurance performance (n = 6), and muscle mass (n = 3,
legs, primary), as well as muscle quality (legs), muscle biology (m. vastus lateralis; muscle fibre characteristics, transcriptome),
and health-related variables (e.g. visceral fat mass and blood lipid profile). For main outcome domains such as muscle strength
and muscle mass, weighted combined factors were calculated from the range of singular assessments.
Results Overall, 13 weeks of resistance training increased muscle strength (13% ± 8%), muscle mass (9% ± 8%), and endur-
ance performance (one-legged, 23% ± 15%; whole-body, 8% ± 7%), assessed as weighted combined factors, and were associ-
ated with changes in health variables (e.g. visceral fat, 6% ± 21%; [LDL]serum, 4% ± 14%) and muscle tissue characteristics
such as fibre type proportions (e.g. IIX, 3% points), myonuclei per fibre (30% ± 65%), total RNA/rRNA abundances (15%/
6–19%), and transcriptome profiles (e.g. 312 differentially expressed genes). Vitamin D3 supplementation did not affect
training-associated changes for any of the main outcome domains, despite robust increases in [25(OH)D]serum (Δ49% vs.
placebo). No conditional effects were observed for COPD vs. healthy or pre-RCT [25(OH)D]serum. In secondary analyses, vitamin
D3 affected expression of gene sets involved in vascular functions in muscle tissue and strength gains in participants with high
fat mass, which advocates further study.
Conclusions Vitamin D3 supplementation did not affect muscular responses to resistance training in older adults with or
without COPD.
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Introduction
Aging is associated with progressive loss of muscle strength
and mass, accompanied by declines in physical performance.
In 2016, this had escalated into ~11 million Europeans
(>65 years of age) suffering from sarcopenia,1 a formally
recognized disease characterized by severe loss of muscle
quantity and quality.1 Sarcopenia increases the likelihood of
adverse events such as falling, fractures, physical disability,
morbidity and mortality,2,3 further fuelling muscle deteriora-
tion, resulting in a spiralling decrease in overall health and
health-related quality of life.4–6 In Europe, the prevalence of
sarcopenia is expected to increase to at least ~19 million
by 2045,1 coinciding with increasing proportions of older
adults, potentiated by suboptimal nutrition and increasing in-
cidences of causal morbidities such as systemic inflammatory
diseases.7,8 For elderly to stay healthy, active and indepen-
dent, efficient interventions are warranted for its prevention,
treatment and reversal.7,8 To this end, lifestyle therapy with
resistance training is an attractive, low-cost and potent
intervention.9,10 Unfortunately, the benefits of such interven-
tions are not always consistent, especially in the older popu-
lation, with selected individuals and populations showing
impaired abilities to increase muscle strength and mass.11,12
At present, this training-response-spectrum has an unknown
causality, although it interdepends on factors such as
genetics,13,14 epigenetics,14 and composites of the inner
physiological milieu, including nutrition,15,16 endocrine vari-
ables (e.g. vitamin D),17,18 and hallmarks of health such as
low-grade chronic inflammation.19 There is thus a need for
development of combinatorial lifestyle protocols that target
and correct these factors alongside resistance training,
thereby allowing adequate muscle adaptations to occur.
Over the last two decades, vitamin D has emerged as a
potential determinant of muscle functionality and biology.20
There seems to be a robust relationship between heteroge-
neity in vitamin D status and traits such as physical
performance21–23 and susceptibility to falling,24 suggesting a
causal association between vitamin D and increased risk of
sarcopenia.25 As such, vitamin D status varies substantially
in the human population, both in an annual cycle, and
between individuals and groups of individuals.26,27 Vitamin
D insufficiency is particularly prevalent in older adults, mea-
sured as 25-hydroxyvitamin D (25(OH)D) levels <50 nmol/L,
and especially in older adults living in the Northern
Hemisphere,27,28 where cutaneous vitamin D synthesis is
miniscule or absent during winter months.29 In accordance
with this, exogenous vitamin D supplementation is gaining
momentum as a potential ergogenic aid for preventing and
treating sarcopenia.25 Unfortunately, the presumed benefits
of vitamin D supplementation deduced from crossover stud-
ies are not necessary supported by data from interventional
studies. While some studies and meta-analyses report
favourable effects of vitamin D supplementation per se on
muscle strength30–32 and falling,33,34 with benefits being
more pronounced in subjects with low baseline values
(<30 nmol/L)35 and in older subjects,35 others do not.36–39
These discrepancies may not be surprising, as resistance
training is arguably necessary to provoke changes in muscle
functions.40 However, a similar ambiguity is present in the
few studies that have assessed the effects of vitamin D
supplementation on outcomes of resistance training.41–44
While none of these studies report clear benefits of vitamin
D supplementation for alterations in muscle strength,41–44
muscle mass,42–44 or incidences of falling,41,43 a recent
meta-analysis still concluded that it provides benefits for
training-associated changes in lower body muscle strength.40
Consequently, we have limited and conflicting knowledge
about the combined effects of vitamin D supplementation
and resistance training for muscle functions and biology
in humans. The present confusion may partly be attributed
to methodological uncertainties in available studies, poten-
tially lowering their ecological validity and explaining
their lack of coherence with the resulting meta-analysis
data. This includes heterogeneous study populations
(varying from young adults42,44 to older adults44 to
elderly41,43) with large differences in baseline 25(OH)D levels
(average 31 nmol/L43–71 nmol/L44), large variation in vitamin
D dosage (from 400 IU/day43–4000 IU/day42), lack of
familiarization to strength tests,41,43 suboptimal training
protocols41,43 (failing to comply to current guidelines, advo-
cating resistance training with controlled maximal effort45,46),
low compliance to training,41,43 and a lack of dietary assess-
ment during the intervention.41,43,44 Also, neither of the stud-
ies included a period of vitamin D supplementation prior to
resistance training, which may be necessary to prime muscle
cells for adaptations, potentially acting by changing epige-
netic traits, which has been observed in other cell types, such
as T-cells47 and oral squamous cell carcinoma cells.48 Further-
more, the effects of vitamin D supplementation on muscle
fibre characteristics and biology remain poorly understood
and unclear.49 In theory, vitamin D may potentiate muscle
fibre responsiveness in two ways. Either directly by acting
through vitamin D receptors in muscle fibres or progenitor
cells, perhaps inducing intramuscular signalling pathways
such as the p38 mitogen-activated protein kinase
pathway,50,51 or indirectly by interacting with systemic signal-
ling event, perhaps inducing testosterone signalling52 and
thereby facilitating muscle plasticity. Our lack of insight is
underlined by the longstanding uncertainty of the presence
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of vitamin D receptors in muscle tissue,53 although several
indications advocate its expression. First, there seems to be
associations between mutations in the vitamin D receptor
and muscle weakness in both humans and mice.54,55 Second,
muscle-specific knock-out of the vitamin D receptor in mice
deteriorates muscle strength and mass in a manner that re-
semble sarcopenia.56,57 The prevailing uncertainty is fuelled
by a seeming lack of effects of vitamin D supplementation
per se on the muscle transcriptome in vitamin D-insufficient
frail elderly, although also in that study the vitamin D dosage
was relatively low (400 IU/day).58 To date, a mere single
study has assessed the effects of vitamin D supplementations
on resistance training-induced muscle biological adaptations
in humans, and as such assessing only a limited selection of
traits and failing to disclose conclusive findings.44
The aim of the present study was to investigate the
effects of 12 weeks of vitamin D3 supplementation only
(the initial two weeks with 10 000 international units
(IU)/day, succeeded by 10 weeks with 2000 IU/day), followed
by 13 weeks of combined vitamin D3 supplementation
(2000 IU/day) and resistance training, on training-associated
adaptations in a mixed population of older subjects. The
RCT thus allowed assessment of responses to both vitamin
D3 supplementation-only and combined vitamin D3 supple-
mentation and resistance training. The study population
included individuals that were either at risk of developing
sarcopenia (age or disease, i.e. COPD patients)59,60 or showed
diagnostic indications of sarcopenia (16.4% of the partici-
pants had appendicular lean mass (kg)/m2 greater than two
standard deviations below the sex-specific means of young
adults).61 Outcome measures included a large range of
muscle strength and endurance performance tests, multiple
assessments of muscle mass, muscle quality, in-depth analy-
ses of muscle biology including muscle fibre characteristics
and analyses of the muscle transcriptome, and a range of
health-related measures including body composition, blood
variables and self-reported health variables.
Methods
Study ethics and participants
The study was approved by the Regional Committee for
Medical and Health Research Ethics - South-East Norway
(reference no: 2013/1094) and was preregistered at
ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT02598830).
All participants were informed about the potential risks and
discomforts associated with the study and gave their
informed consent prior to study enrolment. The study was
conducted according to the Declaration of Helsinki.
Ninety-five male and female participants (age 68 ± 5 years,
range 56–77) were enrolled into the study (Figure 1).
Eligibility criteria were consumption of less than 400 interna-
tional units (IU) of vitamin D3 per day for the two months
leading up to the study, and either normal lung function or
medical diagnosis of COPD (GOLD62 grade II or III, FEV1
predicted between 80% - 30%, FEV1/FVC < 70% after
reversibility testing with inhalation of salbutamol and
ipratropiumbromid). Exclusion criteria were unstable cardio-
vascular disease, chronic granulomatous disease, known
active malignancy within the last five years, serious psychiat-
ric comorbidity, steroid use the previous two months and
musculoskeletal disorders preventing the participant from
participating in the resistance training programme. Initially,
all participants were screened using spirometry and a medical
questionnaire. For healthy participants, this formed the basis
for inclusion. For COPD participants and participants with un-
clear disease status, the initial screening was followed by con-
sultation with a medical doctor to ensure that they met
diagnostic criteria corresponding to GOLD grade II or III,
followed by inclusion. All participants were recreationally ac-
tive, but none had partaken in systematic resistance training
for the 12 months leading up to the study. During study
conduct, all participants were instructed to restrict vitamin
D intake from food sources to <400 IU/day and to abstain
from solarium and travels to southern and/or sunny areas.
Participants were randomly assigned into one of the two
study arms (vitamin D3 vs. placebo) using concealed
allocation, stratified by sex and health status (COPD vs.
non-COPD) (Figure 1 and Table 1). An off-site third party
performed the randomization. During the initial two weeks
of the study, the vitamin D3 arm consumed 10 000 IU vita-
min D3/day, followed by 2000 IU/day for the remainder of
the study period. Placebo capsules contained cold-pressed
olive oil and were identical in appearance to vitamin D3
capsules. Pharma Nord ApS (Vejle, Denmark) produced
the two supplements, complying with Good Manufacturing
Practice requirements. All participants consumed 500 mg
calcium/day (Nycoplus, Takeda AS, Asker, Norway). Vitamin
D status was primarily assessed as 25(OH)D levels in blood
(Figure 2), corroborating with previous studies,63 and
secondarily as 1,25 dihydroxycholecalciferol (1,25(OH)2D;
the biologically active form). 25(OH)D is accepted to be
the most reliable measure of vitamin D status,64 as it is
unaffected by parathyroid hormone (PTH) activity, and is
more stable and represents more accurate measurements
compared with 1,25(OH)2D.
64
Of the 95 participants included in the study, one with-
drew from the study prior to onset on supplementation,
12 withdrew prior to onset of resistance training (vitamin
D3 arm, n = 9; placebo arm, n = 3), and 4 participants
withdrew during the resistance training period (vitamin D3
arm, n = 3; placebo arm, n = 1) (Figure 1). In summary,
78 participants completed the study; 58 healthy partici-
pants and 20 COPD participants. For participant characteris-
tics, see Table 1.
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Study conduct
The study was conducted as a double-blind randomized
clinical trial (RCT), consisting of an initial 12 weeks of
supplementation-only (in average, 3333 IU vitamin D3/day
or placebo; 14 days of 10 000 IU vitamin D3/day, 10 weeks
of 2000 IU/day), followed by 13 weeks of combined supple-
mentation (2000 IU vitamin D3/day or placebo) and resis-
tance training (Figure 2). During study conduct, supplement
allocation was blinded for both participants and investigators.
Unblinding was performed after completion of primary out-
come measure clean-up and analyses. The intervention was
conducted at Lillehammer, Norway (latitude 61°N) from
September to May, ensuring low or no natural vitamin D
synthesis by the skin from sunlight UVB radiation.29 Prior to
onset of the supplementation protocol (i.e. pre-RCT), partici-
pants undertook two weeks of baseline testing and tissue/
blood sampling (Figure 2, Weeks 2 and 1), including test-
ing of unilateral strength and muscle performance (tested
twice, separated by at least 48 h; the first test was performed
at ~95% of maximal effort), lung function, and collection of
fasting blood and rested-state muscle biopsy, sampled from
m. vastus lateralis of the dominant leg using the microbiopsy
technique (Bard Magnum, Bard, Covington, GA, USA). There-
after, participants were randomized to the two supplementa-
tion arms. After two weeks of supplementation, a second
blood sample was collected (Figure 2, Week 2) to validate
the efficacy of vitamin D3 supplementation for blood 25
(OH)D and 1,25(OH)2D levels. Prior to introduction to
resistance training, the participants conducted repeated
Figure 1 CONSORT flow chart of the study.
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performance tests at several occasions (Figure 2, Week
2–Week 13), including unilateral maximal strength and mus-
cular performance, isokinetic unilateral knee-extension
torque, measures of functional capacity (i.e. 6-min step and
1-min sit-to-stand test), submaximal and maximal one-legged
cycling, and maximal bicycling. During the last week before in-
troduction to resistance training (Figure 2,Week 13), bilateral
rested-state biopsies and a fasted blood sample were col-
lected, muscle thickness of m. vastus lateralis and m. rectus
femoris were measured using ultrasound (SmartUs EXT-1 M;
Telemed, Vilnius, Lithuania), and body composition was
measured using dual-energy X-ray absorptiometry scan
(DXA; Lunar Prodigy, GE Healthcare, Chicago, IL, USA).
The training intervention consisted of 13 weeks of two
weekly whole-body resistance training sessions (Figure 2,
Week 14–27). Leg exercises were performed unilaterally to
allow within-participant differentiation of resistance training
load. Accordingly, for each participant, the two legs were ran-
domly assigned to perform either three sets with 10 repeti-
tions to exhaustion (high-load resistance exercise) or three
sets with 30 repetitions to exhaustion (low-load resistance
exercise); that is, each participant performed both protocols
Table 1 Participant characteristics
Vitamin D3 arm Placebo arm
Participants (n) 46 48
Females (n) 24 27
COPD subjects (n) 12 12
Age (years ± SD) 69 ± 5 67 ± 4
Weight (kg ± SD) 75 ± 17 75 ± 16
Lean mass (kg ± SD) 48 ± 11 48 ± 9
Fat percentage (% ± SD) 35 ± 6 34 ± 9
Body mass index (kg/m2 ± SD) 26 ± 5 26 ± 5
1RM knee extension (kg ± SD) 18 ± 8 18 ± 7
1RM chest press (kg ± SD) 47 ± 17 45 ± 16
Withdrawn prior to intro. RT (n) 9 3
Withdrawn after intro. RT (n) 3 1
Renal function
Creatinine (μmol/L) 78 ± 18 80 ± 22
Est. GFR (mL/min/1.73 m2) 80 ± 15 79 ± 15
CKD stage 3, i.e. est. GFR of 30–59 (n) 2 3
Lung function
FVC (L ± SD) 3.4 ± 0.8 3.6 ± 0.9
FEV1/FVC (% ± SD) 67 ± 15 69 ± 14
FEV1 (% predicted ± SD) 87 ± 24 94 ± 26
PEF (L/s ± SD) 6.9 ± 2.4 7.1 ± 2.1
Habitual dietary data
Kilocalories/day ± SD 1777 ± 529 1985 ± 611
Protein (g/kg/day ± SD) 1.26 ± 0.40 1.27 ± 0.36
Fat (g/kg/day ± SD) 0.99 ± 0.47 1.05 ± 0.38
Carbohydrates (g/kg/day ± SD) 2.46 ± 1.05 2.88 ± 1.03
Alcohol (units/day ± SD) 0.76 ± 0.92 0.67 ± 1.04
Vitamin D (IU/day ± SD) 281 ± 235 331 ± 260
Other vitamin D exposures
Number of hours outdoors per week 8.8 ± 6.0 8.9 ± 6.4
Fish for dinner per week 1.9 ± 0.8 1.8 ± 0.7
Fish for other meals per week 2.0 ± 1.7 1.6 ± 1.1
Cod liver oil (teaspoons per week) 1.2 ± 3.8 1.6 ± 3.4
Cod liver oil (capsules per week) 1.5 ± 3.8 2.0 ± 3.8
Number of eggs eaten per week 3.2 ± 1.8 2.9 ± 2.2
Adherence
Adherence to supplementation plan (%) 99 (91–100) 99 (93–100)
Adherence to the training protocol (%) 98 (81–100) 98 (81–100)
Training volume (kg x repetitions) Leg press
Knee
extension RPE Leg press
Knee
extension RPE
Training week 1 (Introduction period, week 1) 4074 (1741) 298 (143) 15.4 (1.4) 4307 (1737) 360 (206) 15.4 (1.5)
Training week 4 (Training period, week 1) 5117 (2199) 364 (187) 15.9 (1.4) 5393 (2247) 407 (201) 16.0 (1.3)
Training week 8 (Training period, week 5) 6071 (2710) 446 (233) 16.5 (1.5) 6200 (2638) 495 (255) 16.6 (1.3)
Training week 13 (Training period, week 10) 6698 (3183) 489 (255) 17.0 (1.3) 6706 (2598) 550 (293) 17.1 (1.2)
1RM, one repetition maximum; CKD, chronic kidney disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GFR, glomer-
ular filtration rate (calculated using the Modification of Diet in Renal Disease study equation; IU, international units; PEF, peak expiratory
flow; RT, resistance training; RPE, rating of perceived exertion (6–20).
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Figure 2 Schematic overview of the study protocol. Pre-defined main time frames (baseline and end time points) for specific outcome measures (the
color lines represents the measurement marked with the same color at the top of the figure; (A), vitamin D-status (25-hydroxyvitamin D levels, (B) and
1,25 dihydroxyvitamin D levels (C) during the RCT, training volume during the resistance training intervention (D), and perceived exertion (Borg RPE,
6–20) reported after training sessions (E). The training volume was calculated as average increase in volume (kg · repetitions) in leg press and knee ex-
tension from the first week of training. STR, maximal strength test; Musc.perf., test of muscular performance; 1-LC, one-legged cycling test; Func., test of
functional capacity (6-min step test and 1-min sit-to-stand test); US, ultrasound measures of muscle thickness; DXA, Dual-energy X-ray Absorptiometry;
V̇O2max, maximal oxygen consumption; IU, international units; RT, resistance training; 25(OH)D, 25-hydroxyvitamin D. In (B), statistical differences be-
tween time points and supplementation arms are denoted by letters: different letter indicates P < 0.05, that is, all time point measures denoted with
the same letter are statistically similar (P > 0.05). Data for 25(OH)D and training volume are presented as means with 95% confidence intervals.
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in each session. For the upper-body, resistance exercises
were performed bilaterally, consisting of two sets of 10 repe-
titions to exhaustion. After seven training sessions (i.e. after
3.5 weeks of training; post-introduction to resistance train-
ing), participants performed a selected battery of tests and
measurements (Figure 2, i.e. Week 17–18), including rested-
state bilateral muscle biopsies, a fasted blood sample, and
measures of muscle strength, performance and torque. These
tests were conducted for two reasons i) to assess the initial
response to resistance training and ii) to reduce the impact
of neural adaptations for training-associated increases in per-
formance (i.e. Week 17–18 was defined as baseline for these
performance measurements). After the training intervention
(post-RCT), the complete battery of tests and measurements
were repeated (Figure 2, i.e. Week 28–30). During week 24,
participants conducted a dietary registration, in which they
logged their dietary intake for 3 days, including one weekend
day (Table 1). Throughout the entirety of the study, partici-
pants completed a weekly health survey every Sunday eve-
ning, which included information about supplementation
compliance, self-reported health and potential discomforts
caused by the nutritional supplement, such as digestive is-
sues, sleep issues, issues with the urinary system, issues with
the vestibular system, and dermal irritations. Moderate ver-
bal motivation was given to all participants during all perfor-
mance tests.
Resistance-exercise training protocol
All participants performed the same whole-body resistance-
exercise training programme, consisting of the following ex-
ercises (listed in order of conductance): unilateral leg press,
unilateral knee extension, unilateral knee flexion, chest press,
and lat pulldown. Leg exercises were performed as three
series of 10 repetitions (high-load) and 30 repetitions (low-
load) to exhaustion (10RM and 30RM, respectively), and
upper-body exercises were performed as two series of 10
repetitions (high-load) to exhaustion, as previously described.
Exercises and sets were separated by 2 min of rest. For leg ex-
ercises, all three sets for one leg were conducted before the
other leg was exercised. The order in which the two legs were
exercised was switched between each session. For all exer-
cises, training loads were adjusted from session to session,
i.e. when participants managed to perform more than 12 or
35 repetitions per set for high- and low-load training, respec-
tively. All sessions were supervised by qualified personnel to
ensure correct technical execution and to ensure maximal ef-
forts through verbal encouragement. To aid recovery and to
ensure adequate protein intake after training, participants
ingested half a protein bar immediately after each training
session (~15 g protein; Big 100, Proteinfabrikken, Sandefjord,
Norway).
Spirometry
Spirometry testing was performed using either the Oxycon
Pro™ with the TripleV digital volume sensor (Carefusion
GmbH, Höchberg, Germany) or the Spirare SPS320 ultrasonic
spirometer (Diagnostica AS, Oslo, Norway) following guide-
lines from the American Thoracic Society and the European
Respiratory Society.65 Importantly, for each particular partici-
pant, all spirometry tests were performed using the same
system. Participants with COPD were tested before and after
inhalation of two bronchodilators (salbutamol, 0.2 mg and
ipratropiumbromid, 20 μg).
Muscle strength and performance
Maximal muscle strength was assessed as one repetition
maximum (1RM) in unilateral knee extension and leg press
(Technogym, Cesena, Italy) and bilateral chest press (Panatta,
Apiro, Italy). Each test started with specific warm-up,
consisting of 10, 6, and 3 repetitions at 40%, 70%, and 85%
of the anticipated maximum. Thereafter, 1RM was found by
increasing the resistance progressively until the weight
could not be lifted through the full range of motion. Loads
were increased in intervals of 1.25, 2.5, and 1.25 kg for
knee extension, leg press, and chest press, respectively. Two
minutes of rest was provided between attempts. Maximal
handgrip strength was measured for the dominant hand
using a hand-held dynamometer (Baseline®, Fabrication
Enterprises, Inc., Elmsford, NY, USA). Each test session
consisted of three attempts, and the average score was
used in further analyses.
Muscle performance was defined as the maximal number
of repetitions achieved at 50% of pre-RCT 1RM and was
assessed in unilateral knee extension and bilateral chest
press. Participants were instructed to lift at a composed
and controlled pace, with <1 s breaks in the lower and upper
position. Whenever this requirement was not met, or partic-
ipants failed to lift the weight through the full range of mo-
tion, the test was aborted.
Isokinetic unilateral knee-extension torque was assessed
using a dynamometer (Humac Norm, CSMi, Stoughton, MA,
USA). Participants were seated and secured with the knee
joint aligned with the rotation axis of the dynamometer. Max-
imal isokinetic torque was tested at three angular speeds
(60°, 120°, and 240° per second) with 2 min of rest provided
between each of them. Prior to each test session, participants
were familiarized with the test protocol by performing three
submaximal efforts at each angular speed. Participants were
given three attempts performed in immediate succession.
The highest value was used in further analyses.
For all tests of unilateral strength and performance, the
dominant leg was tested first. Seat position and general
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settings for each test were noted for each participant and
reproduced at each time-point.
One-legged cycling and bicycling performance
Participants conducted one-legged cycling tests (Excalibur
Sport, Lode BV, Groningen, the Netherlands) to assess O2-costs
of submaximal cycling, and maximal one-legged oxygen con-
sumption (V̇O2max) and power output (Wmax). Each test was
initiated by 2 × 5 min submaximal workloads at 30 and 40
watts (healthy), respectively, or 20 and 30 watts (COPD) with
a cadence of 60 revolutions per minute. Loads were individu-
ally adjusted if the predefined workload was higher than
50% of the Wmax achieved during the familiarization session.
Thereafter, a maximal step-wise incremental protocol was
conducted (10 and 5 watts/min for healthy and COPD partici-
pants, respectively). Starting loads were individually adjusted
to elicit exhaustion after 6–10 min of cycling, based on results
from the familiarization session. The cadence was freely
chosen (>50 rpm). The test was terminated when cadence fell
below 50 rpm. For all participants, submaximal and maximal
performance on the dominant leg was tested first. After test-
ing of the first leg, participants were allowed 20 min rest
and/or low-intensity cycling, before testing of the other leg.
During one-legged cycling tests, a 10 kg counterweight was
attached to the contralateral ergometer crank to facilitate
smooth cycling. The foot of the non-exercising leg was rested
on a chair placed in front of the subject. Breath-to-breathmea-
surements of pulmonary oxygen consumption and ventilation
(JAEGER Oxycon PRO™; Carefusion GmbH, Höchberg,
Germany) and heart rate (Polar Electro Oy, Kempele, Finland)
was monitored continuously during all tests. The average oxy-
gen consumption during the last 2 min of each submaximal
workload was defined as the O2-cost, while V̇O2max was
defined as the highest average oxygen consumption measured
over a period of 30-s. Measurement of capillary lactate
concentration (Biosen C-line, EKF Diagnostics, Barleben,
Germany) was performed after finalization of tests.
Testing of maximal bilateral cycling V̇O2max and Wmax was
performed on a separate day. A step-wise incremental proto-
col (20 and 15 watts/min for healthy men and women,
respectively; 10 watts/min for participants with COPD) was
conducted. Oxygen consumption was measured continuously
using a computerized metabolic system with mixing chamber
(JAEGER Oxycon PRO™; Carefusion GmbH, Höchberg,
Germany). Prior to each cycling test, the gas analyser was
calibrated using certified calibration gases with known con-
centrations, and the flow turbine (TripleV; JAEGER,
Carefusion GmbH, Höchberg, Germany) was calibrated using
the metabolic system’s automatic volume calibration, or a
3 L, 5530 series calibration syringe (Hans Rudolph Inc., Kansas
City, MO, USA), for one-legged and bicycling tests,
respectively.
Functional performance
One-minute sit-to-stand and 6-min step tests were conducted
in consecutive order on the same test day. Each test session
was initiated with 10 min warm-up of low-intensity bicycling.
Briefly, during the 1-min sit-to-stand tests, participants were
instructed to fold their arms and sit/stand up for as many
times possible during a 1-min period. The seat was 45 cm
from the floor. Sit-to-stand repetitions were approved if both
knees and hip joints were fully extended after each seating.
Three minutes after the 1-min sit-to-stand test, the 6-min
step test was conducted. Briefly, participants were instructed
to perform as many steps as possible onto a 20 cm high step
box with a non-slip rubber surface within 6 min (Reebok Step;
Boston, MA, USA). During each step, participants were
instructed to place both legs on the box, with the hip fully
extended.
Muscle thickness by ultrasound and dual-energy
X-ray absorptiometry-derived body mass measures
Prior to measurements of muscle thickness and DXA mea-
surements, the participants were instructed to attend an
overnight fast and avoid heavy physical activity for the last
24 h leading up to the event.
Muscle thickness of m. vastus lateralis and m. rectus
femoris were measured using B-mode ultrasonography
(SmartUs EXT-1 M, Telemed, Vilnius, Lithuania) with a
39 mm 12 MHz, linear array probe. Transverse images were
obtained ~60% distally from the trochanter major towards
the femoral lateral epicondyle. Three images were captured
for each muscle, where the probe was relocated to the
same position between each image. The position of the
probe was marked on the skin and subsequently marked
on a soft transparent plastic sheet superimposed on the
thigh. Landmarks such as moles and scars were also
marked on the plastic sheet for relocation of the scanned
areas during post-training measurements. During analysis,
pre and post images from the same participant were
analysed consecutively using the Fiji software66 and by
two independent researchers. The average muscle thickness
of the three images captured per muscle was used for fur-
ther analyses.
Body composition was determined using DXA (Lunar
Prodigy, GE Healthcare, Madison, WI, USA) and was analysed
using the manufacturer’s software, in accordance with the
manufacturer’s protocol. Leg lean mass was defined as the
region distally of collum femoris. Care was taken to match
the region of interest on pre and post images. Analyses of
both muscle thickness and body composition were per-
formed in a blinded manner regarding participant identity
and time point of the measurement.
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Blood sampling and measurements, and muscle
biopsy sampling
Prior to collection of blood and muscle biopsies, participants
were instructed to attend an overnight fast and to avoid
heavy physical activity for the last 48 h leading up to the
event. All blood samples and muscle biopsies were collected
between 08:00 and 11:00 a.m. Blood samples were collected
from an antecubital vein into serum-separating tubes and
kept at room temperature for 30 min before centrifugation
(2600 g, 15 min). Serum was aliquoted and stored at 80°C
until further processing. Serum concentrations of total
testosterone, cortisol, growth hormone, insulin-like growth-
factor 1 (IGF-1), sex-hormone binding globulin (SHBG) and
androstenedione were measured using an Immulite 2000
analyser with kits from the Immulite Immunoassay System
menu (Siemens Medical Solutions Diagnostics, Malvern, PA,
USA). Serum 25(OH)D, parathyroid hormone, calcium, albu-
min, creatinine, creatine kinase, aspartate aminotransferase,
C-reactive protein, triglycerides, low-density lipoprotein,
high-density lipoprotein, thyroid hormones and iron metabo-
lism variables were measured using a Roche Cobas 6000
analyser and kits from Roche (Roche Diagnostics, Rotkreuz,
Switzerland). In a subset of participants, 1,25(OH)2D levels
in serum were measured at Week 1, Week 2, Week 13
and Week 28 (vitamin D3 arm, n = 19; placebo arm, n = 21)
using enzyme immunoassays with kits from Immunodiagnos-
tic Systems (IDS, Boldon, Tyne & Wear, UK).
Muscle biopsies were sampled from m. vastus lateralis un-
der local anaesthesia (Lidocaine, 10 mg/mL, AstraZenaca AS,
Oslo, Norway) using a 12-gauge needle (Universal Plus,
Medax, San Possidonio, Italy) operated with a spring-loaded
biopsy instrument (Bard Magnum, Bard, Covington, GA,
USA), as previously described.67 Biopsies were sampled at
1/3 of the distance from the patella to the anterior superior
iliac spine. The tissue was quickly dissected free of blood
and visible connective tissue in ice-cold sterile saline solution
(0.9% NaCl). Samples for immunohistochemistry were trans-
ferred to a 4% formalin solution for fixation for 24–72 h,
before further preparation. Samples for RNA analyses were
blotted dry, snap-frozen in isopentane (80°C) and stored
at 80°C until further processing.
Immunohistochemistry
Formalin-fixed muscle biopsies were processed rapidly using
a Shandon Excelsior ES (Thermo Fisher Scientific, Waltham,
MA, USA), whereupon biopsies were paraffin-embedded
and sectioned into transverse sections (4 μm). Antigen
retrieval was performed at 97°C for 20 min in a target
retrieval solution (cat. no. DM828, Agilent Dako, Santa Clara,
CA, USA) using a PT link (PT 200, Agilent Dako, Santa Clara,
CA, USA). Staining was performed using a DAKO Autostainer
Link 48 (Agilent Dako, Santa Clara, CA, USA). For determina-
tion of muscle fibre types, cross-sections were first treated
with protease 2 (cat. no. 760–2019, Roche Diagnostics,
Rotkreuz, Switzerland), before they were triple-stained using
2.5 μg/mL BA-F8, BF-35 and 6H1 (all from Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City, IA,
USA; BA-F8 and BF-35 deposited by Schiaffino, S., Uni. of Pa-
dova, Italy; 6H1 deposited by Lucas, C., Uni. of Sydney,
Australia). Visualization of the primary antibodies was
achieved by incubation of appropriate secondary antibodies,
diluted 1:400: goat anti-mouse Alexa Fluor (Thermo Fisher
Scientific, Waltham, MA, USA) 350 (IgGγ2b, cat. no.
A21140), 488 (IgGγ1, cat. no. A21121) and 594 (IgM H + L,
cat. no. A21044) for BA-F8, BF-35 and 6H1, respectively.
For determination of muscle fibre cross-sectional area
(CSA) and numbers of myonuclei per muscle fibre type, a dif-
ferent tissue cross-section was double-stained using primary
antibodies against muscle fibre membrane (dystrophin, di-
luted 1:100, cat. no. PA1–21011; Thermo Fisher Scientific,
Waltham, MA, USA) and myosin heavy chain I (diluted
1:2000, cat. no. M8421, Sigma-Aldrich, Saint-Louis, MO,
USA). Visualization was achieved using the secondary anti-
bodies Alexa Fluor 594 (IgG H + L, diluted 1:400, cat. no.
A11037) and 488 (IgG1γ1, diluted 1:400, cat. no. A21121), re-
spectively (Thermo Fisher Scientific, Waltham, MA, USA).
Muscle sections were then covered with a coverslip and
glued with EverBrite™ Hardset Mounting Medium with DAPI
(cat. no. 23004, Biotium Inc., Fremont, CA, USA), to visualize
cell nuclei.
Images of stained cross-sections were captured using a
high-resolution camera (Axiocam, Zeiss, Oberkochen,
Germany) mounted on a light microscope (Axioskop-2, Zeiss,
Oberkochen, Germany), with a fluorescent light source
(X-Cite 120, EXFO Photonic Solutions Inc., Mississauga,
Canada). Multiple images were taken using 20× objectives
to capture the entirety of each cross-section. For representa-
tive images, see Figure 3. All analyses of muscle fibre charac-
teristics were performed using automated procedures,
ensuring unbiased quantification.
Analyses of muscle fibre type proportions were performed
using the Cell Counter function in the Fiji software,66
whereby muscle fibres were categorized as either type I, type
IIA, type IIX or hybrid fibres type IIA/IIX. Sections and/or
images with insufficient staining to distinguish between fibre
types were excluded. Muscle fibre type-specific CSA (type I or
type II) were calculated using the TEMA software
(CheckVision, Hadsund, Denmark). Myonuclei were counted
using the CellProfiler software.68
Total RNA extraction and qPCR
Approximately 10–20 mg of wet muscle tissue (average
13 ± 4 mg, range 3–26 mg) was homogenized in a total
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volume of 1 mL TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
using 0.5 mm RNase-free zirconium oxide beads and a bead
homogenizer (Bullet Blender, Next Advance, Averill Park, NY,
USA), as previously described.67 To enable analysis of target
gene expression per unit tissue weight, an exogenous RNA
control (λ polyA External Standard Kit, Takara Bio Inc., Shiga,
Japan) was added at a fixed amount (0.04 ng/mL of Trizol re-
agent) per extraction prior to homogenization, as previously
described.69,70 Following phase separation, 450 μL of the
upper phase was transferred to a new tube and RNA was pre-
cipitated using isopropanol. The resulting RNA pellet was
washed three times with 75% ethanol, eluted in 30 μL TE
buffer, and diluted to 100 ng RNA/μL, following quantification
of total RNA concentration using μDrop plate and the
Multiskan GO microplate spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA). RNA integrity was
assessed using capillary electrophoresis (Experion Automated
Electrophoresis Station using RNA StdSens Assay, Bio-Rad,
Hercules, CA, USA) with average integrity score (RNA quality
indicator; RQI): 8.9 ± 0.8.
Five hundred nanograms of RNA were reverse transcribed
using anchored oligo-dT (Thermo Fisher Scientific, Waltham,
MA, USA), random hexamer primers (Thermo Fisher
Scientific, Waltham, MA, USA) and Super-Script IV Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA), according to
manufacturers’ instructions. All samples were reverse tran-
scribed in duplicates and diluted 1:50 prior to quantitative
real-time polymerase chain reaction (qPCR). qPCR reactions
were conducted using a fast-cycling real-time detection sys-
tem (Applied Biosystems 7500 fast Real-Time PCR Systems,
Life Technologies AS), with total volumes of 10 μL, containing
2 μL cDNA (1:25 dilutions), target gene-specific primers (final
concentration 0.5 μM) and a commercial master mix (2× SYBR
Select Master Mix, Applied Biosystems, Life Technologies
Corp., Carlsbad, CA, USA). qPCR reactions consisted of 40 cy-
cles (3 s 95°C denaturing and 30 s 60°C annealing).
Melt-curve analyses were performed for all reactions to ver-
ify single-product amplification. Gene-specific primers were
designed using Primer3Plus71 and synthesized by Thermo
Scientific, except for the external RNA control, for which
primers were supplied with the kit (λ polyA External Standard
Kit, Takara Bio Inc., Shiga, Japan). Raw fluorescence data were
exported from the platform-specific software and amplifica-
tion curves were modelled using a best-fit sigmoidal
model using the qpcR-package72 written for R.73 Threshold
cycles (Ct) were estimated from the models by the
second-derivate maximum method with technical duplicates
modelled independently. Amplification efficiencies were esti-
mated for every reaction.74 For every primer pair, mean am-
plification efficiencies (E) were utilized to transform data to
the linear scale using E–Ct. Primer sequences and primer
characteristics (i.e. average primer efficiencies and Ct values)
are presented in Supporting Information, Table S1. Gene
expression data were log-transformed prior to statistical
analysis. As Ct values, but not primer efficiencies depend on
RNA integrity,75 RQI scores were used as a random variable
on a per-target basis to control for potential degradation dur-
ing statistical analyses (see below).
RNA sequencing
RNA sequencing was performed on pairwise muscle samples
collected before the RCT (vitamin D3, n = 11; placebo, n = 13),
after 12 weeks of supplementation-only (vitamin D3, n = 24;
placebo, n = 29), after 3.5 weeks of introduction to resistance
training (vitamin D3, n = 23; placebo, n = 28), and after
13 weeks of resistance training (vitamin D3 arm, n = 24; pla-
cebo arm, n = 29). Samples was selected based on quality
of total RNA samples (RQI > 7.0, avg 9.0 ± 0.5). Participants
with complete sets of muscle biopsies were prioritized. For
each muscle sample, mRNA sequencing libraries were pre-
pared from 1000 ng of total RNA using TruSeq Stranded Total
RNA Library Prep (Illumina, San Diego, CA, USA). Paired-end
sequencing (150 bp) was performed using an Illumina HiSeq
Figure 3 Representative immunohistochemistry images of (A) myosin heavy chain I (green) and cell membrane (red), (B) myonuclei (blue) and cell
membrane (dystrophin, red), and (C) myosin heavy chain I (blue), IIA (green), IIX (red), and IIA/IIX hybrids (orange). Images in (A) and (B) are from
the same tissue cross-section: triple-staining myosin heavy chain I, dystrophin and cell nuclei.
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3000 (Illumina, San Diego, CA, USA) at the Norwegian
Sequencing Centre, Oslo, Norway.
Data analyses and statistics
As defined in the pre-registration of the study protocol
(ClinicalTrials.gov Identifier: NCT02598830), the effects of vi-
tamin D3 supplementation for different outcome measures
were evaluated using different baseline time points (outlined
in Figure 2). For transparency, statistical comparisons of all
outcome measures and all relevant time points are presented
in Supporting Information, Tables S2 and S3. These tables also
specify the statistical models used for each specific variable
and analysis. In general, for continuous variables, the effects
of vitamin D3 supplementation (compared with placebo)
were investigated using linear mixed-effects models with
the relative change from baseline being defined as the
dependent variable and the supplementation arms being de-
fined as the fixed effect. The two different training loads
(high- and low-load) were added to the model as repeated
measures/observations (for unilateral outcome measures),
and baseline values were used as co-variates. For all partici-
pants, random intercepts were specified. For all unilateral
leg variables, interaction effects were explored between the
fixed effect and health status (COPD vs. non-COPD) and train-
ing loads. For other variables, interactions were investigated
between the fixed effect (vitamin D3 vs. placebo) and health
status, with the exception for blood variables, for which the
interaction with sex was also examined. For all statistical
analyses of immunohistochemical variables (muscle fibre
CSA, fibre type proportion, and myonuclei per fibre), the
models were weighted for the number of counted fibres
per biopsy. This was carried out to account for the
reduced reliability accompanying fewer observations/fibres
(see Supporting Information, Figure S2). For non-continuous
variables, a different statistical approach was used to investi-
gate the effects of the vitamin D3 supplementation. For fibre
type proportions (immunohistochemistry) and variables from
the weekly health survey, a generalized linear mixed model
(GLMM) with binomial error distribution and link function
was used to examine differences in changes between supple-
mentation arms (time*supplementation arm interactions).
For gene family-based analyses of myosin heavy-chain mRNA
data,76 a GLMM with negative binomial distribution/link
function (log-link) was used following transformation to tran-
script counts.77 Target gene mRNA abundance, expressed as
per unit muscle weight using the external reference gene,
were analysed using mixed linear models with within-model
normalization through the addition of random effects of
technical replicates. To allow for gene-specific variances, var-
iance functions were specified per strata (per gene). RQI
scores were included in the model on a per target basis to
control for RNA degradation. The number of observations
per statistical analysis is presented in Supporting Information,
Table S2. For most outcome measures, the main effect of
time was examined using mixed modelling, using absolute
values for the dependent variable and time points as re-
peated measures/observations with random intercepts for
each subject (Supporting Information, Table S2 for complete
overview).
During transcriptome analyses, gene counts were modelled
using negative binomial GLMM with the total library size
modelled as a fixed effect78 together with sex and study con-
ditions (time point and supplementation arms). The effect of
resistance training on gene counts was assessed as i) the ef-
fect of time and ii) its interaction with supplementation arm
(vitamin D3 and placebo supplementation). For analyses of
the effect of time, differential expression was evaluated using
GLMMs containing only the time factor, combining all data ir-
respective of supplementation arm. For analyses of the effect
of supplementation over time, differential expression was
evaluated using GLMMs containing the interaction between
time and supplementation arm. The supplementation-only
period was modelled independently of the training period.
In all models, a single random effect was used, giving each
participant an individual intercept. Models were iteratively
fitted using glmmTMB.79 Model adequacy was tested for each
model fit by assessing uniformity of simulated residuals.80 A
total of 15 093 genes were included in the RNA-seq data set
after initial filtering, and 0.4–3.7% of these were subsequently
removed due to violation of the uniformity assumption
(P < 0.05). Genes were identified as differentially expressed
when the absolute log2 fold-change was greater than 0.5
and the adjusted P-value (false discovery rate adjusted per
model coefficient) was below 5%. Enrichment analyses of
gene ontology (GO) gene sets were performed using two
approaches. First, a non-parametric rank test81,82 was
performed based on gene-specific minimum significant differ-
ences (MSD). MSD was defined as the lower limit of the 95%
confidence interval (CI, based on estimated standard errors)
around the log fold-change (FC) when log (FC) > 0 and the
negative inverse of the upper 95% CI when log (FC)< 0. Genes
with MSD < 0 were further ranked based on P-values. The
rank test assessed non-directional changes in gene sets. Sec-
ond, gene set enrichment analysis (GSEA)83 was performed
to quantify directional regulation of the gene set. GSEA was
performed using the fgsea package,84 with log10(P-values)
*log2(fold-change) acting as the gene level metric.
85 Consen-
sus results between the two analyses were given higher
importance. GO gene sets (biological process, cellular compo-
nent and molecular function), as well as Hallmark and KEGG
gene sets were retrieved from the molecular signature data-
base (version 7.1).86 Overview of enrichment analyses with
exact P-values are presented in Supporting Information,
Tables S5, S6, and S8–S10.
To achieve reliable assessment of the main outcome do-
mains muscle strength, muscle mass, one-legged endurance
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performance and whole-body endurance performance, and
thus to lower the risk of statistical errors, combined factors
were calculated for outcome measures. For complete over-
view over the composition of each factor, see Supporting
Information, Table S4. During factor calculation, each of the
underlying variables were normalized to the participant with
the highest value recorded during the RCT, resulting in
individual scores ≤1. Thereafter, outcome domain factors
were calculated as the mean of the normalized values for
each variable for each subject (e.g. the muscle mass factor
of the legs included muscle thickness, leg lean mass, and
muscle fibre CSA). To evaluate the biological coherence of
these factors, a factor analysis was performed to ensure
correlation between the combined factors and their underly-
ing outcome variables (Supporting Information, Table S4).87
To assess the effect of vitamin D3 supplementation for
changes in these combined factors, linear mixed-effects
models were used, as previously described. In addition, these
factors were used to investigate the influence of pre-RCT
levels of 25(OH)D, body fat proportions and body mass index
on the effects of vitamin D3 supplementation. To perform
these analyses, each of the two supplementation arms were
divided into quartiles, defined by baseline 25(OH)D, body
fat percentage and body mass index levels, respectively
(quartile 1, lowest, … quartile 4, highest). For each of the
calculated factors, the effect of quartile and the interaction
between quartile and supplementation arm was examined
using mixed modelling.
Statistical significance was set to P < 0.05. In the text, data
are presented as means ± standard deviation. In figures, data
are shown as adjusted, estimated marginal means of relative
changes and differences in relative changes between supple-
mentation arms, with 95% confidence intervals, unless other-
wise stated. Statistical analyses were performed using SPSS
Statistics package version 24 (IBM, Chicago, IL, USA) and R
software.73 Figures were made using Prism Software
(GraphPad 8, San Diego, CA, USA) and R software.73
Results and discussion
Effects of vitamin D3 supplementation on 25(OH)D
and 1,25(OH)2D in blood
At pre-RCT, participants in vitamin D3 and placebo interven-
tion arms had similar [25(OH)D] levels in serum (80 nmol/L
vs. 78 nmol/L, range: 24–144 nmol/L, Figure 2). [25(OH)D]
levels did not differ between participants with different
health status (i.e. with or without COPD diagnosis). In
the vitamin D3 arm, the study was initiated by 14 days
of high-dosage vitamin D3 intake (10 000 IU per day), which
led to 42 nmol/L increases in [25(OH)D] (to 122 ± 24 nmol/L;
range = 82–175 nmol/L; P < 0.001), with no change in the
placebo arm (79 ± 31 nmol/L; range = 36–167 nmol/L) (Figure
2). During the remainder of the study (weeks 3–30), vitamin
D3 was ingested at 2000 IU per day, which led to stabilization
of [25(OH)D] at elevated levels compared with the placebo
arm (Week 13, Δ45 nmol/L; Week 17, Δ49 nmol/L; Week 29,
Δ46 nmol/L; Figure 2), resembling the efficacy of previous
studies with comparable study protocols (~2500 IU per
day).88,89 Conversely, in the placebo arm, [25(OH)D] either de-
clined or was similar to pre-RCT levels (Week 13, 8 nmol/L;
Week 17,11 nmol/L; Week 29,6 nmol/L; Figure 2), corrob-
orating with changes typically seen in Northern populations
during winter months,27 with the notable observation that
values were slightly higher than expected.28
After the initial 14 days of supplementation-only, the
marked increases in 25(OH)D in the vitamin D3 arm were ac-
companied by robust increases in [1,25(OH)2D] compared
with the placebo arm (vitamin D3, +17 pmol/L; placebo,
7 pmol/L; Δ24 pmol/L, P = 0.004; Figure 2). During this time
frame, change scores for [1,25(OH)2D] were correlated with
change scores for [25(OH)D] (r = 0.429, P = 0.006; data not
shown). At Week 13 and 29, the statistical difference in
changes in [1,25(OH)2D] between supplementation arms
had disappeared (Δ11 pmol/L, P = 0.377, and Δ12 pmol/L,
P = 0.224; Figure 2), and the correlation between changes
in [1,25(OH)2D] and [25(OH)D] was no longer evident
(r = 0.169–0.243, P = 0.131–0.298; data not shown). The
initial period of high-dosage vitamin D3 supplementation thus
led to rapid elevations in 1,25(OH)2D levels, which was subse-
quently reversed towards baseline levels during the follow-up
period with maintenance intake (2000 IU/day), although
vitamin D3 supplementation was still associated with
increased numerically values and the levels of individual
variation was large. In all but three samples, measures
of [1,25(OH)2D] were within the normal range for adults
(39–193 pmol/L), as defined by the manufacturer,90 with all
deviating samples being >193 pmol/L (vitamin D3, n = 2;
placebo, n = 1).
At the onset of introduction to training (Week 13) and
throughout the training intervention (Week 17, Week 29),
participants in the vitamin D3 arm were all vitamin D-suffi-
cient, as classified by the National Academy of Medicine
([25(OH)D] > 50 nmol/L),27 while in the placebo arm, 13
(Week 13), 12 (Week 17) and 5 (Week 29) participants were
vitamin D-insufficient. In both supplementation arms, cal-
cium was ingested at 500 mg/day throughout the interven-
tion. Despite this, no changes were seen in calcium or
albumin-corrected calcium levels in blood at any time point
(Supporting Information, Table S11). Levels of the parathyroid
hormone decreased throughout the intervention (P = 0.035;
Supporting Information, Table S11), most likely caused by
an autoregulatory response to increased calcium intake.91
Vitamin D3 supplementation did not alter this response.
Compliance to the supplementation protocol was high in
both intervention arms (vitamin D3, 99.3%; placebo, 99.3%;
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P = 0.998). Together, these observations suggest that vitamin
D3 supplementation led to improved vitamin D-status during
the intervention, measured as 25(OH)D, whereas placebo led
to reduced or maintained levels, with approximately 1/3rd of
placebo-receiving participants showing levels associated with
impaired muscle functionality (<50 nmol/L) at the onset of
resistance training.21,22,92
Effects of vitamin D3 supplementation on
resistance training-associated changes in myofibre
cross-sectional area and proportions (primary
objectives)
In contrast to our main hypotheses, vitamin D3 supplementa-
tion did not enhance resistance training-associated increases
in muscle fibre cross-sectional area or changes in muscle fibre
proportions (Figure 4; pre-defined as primary objectives of
the study), despite clear improvements in vitamin D status
(25(OH)D). The results are presented in more detail in
later sections (Effects of vitamin D3 supplementation on
training-associated changes in maximal muscle strength and
lower-limb muscle mass and Effects of vitamin D3
supplementation on training-associated changes in muscle
fibre characteristics and transcriptomics).
Effects of 12 weeks of vitamin D3-supplementation
only (weeks 1–12) on muscle strength,
performance and characteristics
The main purpose of the initial 12 weeks of vitamin D3
supplementation-only was to ensure physiologically elevated
[25(OH)D] for a prolonged period prior to onset of resistance
training, thus potentially priming muscle cells for plasticity.
Vitamin D3 supplementation itself had no effect on upper-
and lower-body muscle strength and performance, muscle fi-
bre area and characteristics (m. vastus lateralis), or hormone
concentrations in blood compared with placebo (Supporting
Information, Figure S1 and Table S2), showing no interaction
with health status. Surprisingly, the only exception was 1RM
knee extension, for which vitamin D3 led to negative changes
compared with placebo (Δ8.4%; P = 0.008), opposing the
seemingly accepted dogma that vitamin D supplementation
per se exerts positive effects on leg muscle strength.35,93
Notably, for all muscle strength and muscular performance
variables, the initial 12 week supplementation period was
Figure 4 Primary outcome objectives of the study; effects of combined vitamin D3 supplementation and resistance training on changes in muscle fibre
cross-sectional area (A, B) and fibre type proportions (C–E) in older adults. Alpha level at P < 0.05. Data are presented as means with 95% confidence
intervals.
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associated with improved performance in all performance
tests (5–71%; for details, see Supporting Information,
Figure S1). These improvements occurred without any appar-
ent changes in muscle cell characteristics in thigh muscle, in-
cluding muscle fibre CSA (type I, 4%, P = 0.573; type II, 9%,
P = 0.312), muscle fibre type proportions (P = 0.127–0.901),
and total RNA/rRNA expression (P = 0.604–1.000)
(Supporting Information, Figure S1). They were hence likely
caused by technical, psychological and neural learning
effects,94 effectuated by repeated exposure to testing prior
to and during the supplementation period (Supporting
Information, Figure S1), as is typically seen in older
subjects.95 Indeed, dynamic exercises like knee extension
and chest press are associated with lower intra-rater reliabil-
ity than the grip strength test,94 which remains unaffected by
test–retest,94 as was likely the case in the present study.
Overall, the 12-weeks supplementation-only period did
not lead to marked changes in mRNA transcriptome pro-
files in the two supplementation arms combined (vitamin
D3, n = 11; placebo, n = 13). Vitamin D3 supplementation
was, however, associated with differential changes in the
expression of a selected genes compared with placebo; 27
genes ↑ and 27 genes ↓ (Figure 5A and Supporting
Information, Table S7). This included increased expression
of B-cell lymphoma 6 and prolyl 4-hydroxylase subunit
alpha-1 (BCL6 and P4HA1; Figure 5A), both of which are
known to oppose accumulation of reactive oxygen species
(ROS),96–98 and decreased expression of angiopoietin-like
protein 4 (ANGPTL4; Figure 5A), which is closely correlated
with levels of mitochondrial respiration.99 These findings
were reaffirmed by gene enrichment analyses, which
showed a general reduction in the expression of gene sets
relating to both oxidative and glycolytic metabolism in the
vitamin D3 arm (Figure 5B and Supporting Information,
Tables S5–S6). This is in line with previous observations
whereby vitamin D has been shown to counteract ROS
and mitochondrial oxidative stress.100 The seemingly nega-
tive effect of vitamin D3 supplementation for expression
of mitochondrial genes may thus be due to reduced
mitochondrial turnover. Of note, expression of the vitamin
D receptor (VDR) was observed in the data set, but was
not affected by supplementation.
Figure 5 Effects of 12 weeks of vitamin D3 supplementation-only on whole-genome transcriptome profiles in m. vastus lateralis of older adults. After
12 weeks of supplementation-only, numerous genes were differentially expressed between the vitamin D3 and the placebo arm (A); Δ,
pre-introduction to resistance training/pre-RCT). Gene ontology (GO) enrichment analyses showed that these genes were primarily related to mito-
chondrial function and cell cortex/cell-substrate junction (B); positive/negative GSEA-normalized enrichment scores indicates higher/lower expression
of gene sets in the vitamin D3 arm compared with the placebo arm). The seven differentially expressed gene sets were clustered into two distinct
groups of genes (C).
612 K.S. Mølmen et al.
Journal of Cachexia, Sarcopenia and Muscle 2021; 12: 599–628
DOI: 10.1002/jcsm.12688
Introductory observations on the quality and
general efficacy of the resistance training protocol
(weeks 13–28)
Before assessing the effects of combined vitamin D3
supplementation and resistance training, it is vital to reaffirm
that the protocols and methods held sufficient validity and
reliability, including a general assessment of the efficacy of
the resistance training intervention. All training sessions were
supervised by qualified personnel, as suggested by others,46
which likely contributed to the very low drop-out rate
(n = 4 during the training period, ~5%, Table 1), and ensured
high adherence to the protocol (98%, range 81–100%, Table
1) and appropriate training progression throughout the
intervention (Figure 2). Training volume (repetitions x kg)
increased by 20% (knee extension) and 30% (leg press) from
Week 14 (the first week of training) to Week 18 (the 4th
week of training), by 48% and 54% to Week 22 (the 8th week
of training) and by 65% and 68% to Week 27 (the last week of
training) (Figure 2). This resembles or exceeds training pro-
gression seen in similar studies on previously untrained
participants101,102 and was accompanied by progressive
increases in perceived exercise intensities (using the Borg
RPE-scale103) (Figure 2). For these training characteristics,
no differences were observed between supplementation
arms (P = 0.897–0.980). The arguably successful completion
of the resistance training intervention was accompanied
by marked functional and biological adaptations in the
participants, including increased muscle strength and perfor-
mance (e.g. 22% and 72% increases in 1RM and muscular
performance in knee extension, respectively, P < 0.05,
Supporting Information, Figure S1), increased muscle mass
(e.g. 16–24% increases in muscle fibre CSA for m. vastus
lateralis, P < 0.05, Supporting Information, Figure S1),
increases in myonuclei number per fibre (30–37%, P < 0.05,
Supporting Information, Figure S1), alterations in muscle fibre
proportions (e.g. type IIX fibre proportions changed from 10%
to 7%, P < 0.05, Supporting Information, Figure S1), and
robust alterations in muscle transcriptome profiles (499 and
312 differentially expressed genes at post-introduction resis-
tance training and post-RCT, compared with pre-introduction
to resistance training, Figure 11A,B). Importantly, neither of
these muscle fibre characteristics changed from pre-RCT to
before onset of resistance training (Week 13), suggesting
that muscle biopsies sampled before and after the
supplement-only period could be regarded as a sampling-
resampling event (Supporting Information, Figure S1). For
muscle strength, the intervention had relative efficiencies of
0.86% (knee extension) and 1.43% (leg press) increase per
session, which resemble or exceeds expectations based on
previous studies of untrained older adults (0.5–1.0% per
session).104–106
Analytical measures to increase the validity of
vitamin D3-based analyses
To ensure valid analyses of the effects of vitamin D3
supplementation on muscle-related features, two precaution-
ary measures were deemed to be necessary. First, for muscle
strength and muscle performance (apparatus exercises),
we defined baseline levels to be equivalent to values
collected after 3.5 weeks of introduction to resistance
training (main analyses, Figure 2), rather than values
collected before its onset, as noted in the preregistration of
the study (NCT02598830). At this time point, initial adapta-
tions to training were likely to have occurred, preferably
non-hypertrophic effects relating to technical, psychological
and neural learning effects,94 phenomena that are particu-
larly prominent in older subjects.95 Using this time point as
baseline arguably strengthens the association between
changes in muscle strength and muscle mass, which was
the main perspective of our vitamin D3-based analyses. For
other outcome measures, baseline levels were either defined
as values obtained at the onset of introduction to resistance
training (Figure 2, Week 13; muscle biological data, muscle
thickness, body composition, endurance-related outcome
measures) or as values obtained pre-RCT (Week 1, Figure 2;
self-reported health, blood variables, lung function).
To further minimize the confounding effects of
non-hypertrophic increases in strength and performance, all
participants conducted a series of repeated tests prior to base-
line tests, including five repeated 1RM and muscular perfor-
mance tests in knee extension and chest press (Supporting
Information, Figure S1a,b,e,f), respectively, four of which was
conducted prior to onset of introduction to training. As ex-
pected, this led to marked and progressive increases in
strength/performance levels for all test procedures compared
with pre-RCT values (e.g. 4–8 – 14% for 1RM knee extension,
3–5 – 13% for 1RM bench press; the first test was conducted
at ~95% of maximal effort and was thus removed from analy-
ses) (Supporting Information, Figure S1). For leg press, three
tests were performed prior to the defined baseline test at
post-introduction to resistance training, resulting in similarly
scaled improvements as observed for knee extension and
chest press (Supporting Information, Figure S1, 14%; the first
test was conducted at ~95% of maximal effort and was thus re-
moved from analyses). These improvements occurred without
any apparent hypertrophy in m. vastus lateralis of the domi-
nant leg, measured as muscle fibre CSA (pre-RCT vs.
pre-introduction to resistance training; type I, P = 0.573;
type II, P = 0.312), as previously presented (Supporting
Information, Figure S1g), strengthening the notion that the im-
provements were due to other factors. After adopting the
post-introduction-to-training time point as baseline for the
strength outcome measures, the efficiency of the intervention
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on muscle strength was still somewhat higher than expected
based on previous observations104–106 (1RM knee extension,
0.8% per session; 1RM leg press, 1.3% per session). Notably,
while these former studies contained less extensive measures
to ensure reproducibility, they reported low test–retest
variability, which does not concur with our results.104–106
Second, for analyses of the effects of vitamin D3 supple-
mentation on changes in muscle mass, we found it necessary
to reconsider our choice of using changes in muscle fibre CSA
and fibre type proportions in m. vastus lateralis as the pri-
mary objective of the study. These data were associated with
large degrees of sampling-to-resampling variation, as evalu-
ated using repeated muscle biopsies from the dominant leg,
sampled at weeks 1 and 13, i.e. prior to introduction to
resistance training (Supporting Information, Figure S2). Simi-
lar issues have been previously reported for such analyses,107
although not in all studies108,109 and are likely exacerbated in
older adults, for whom larger spatial heterogeneity are pres-
ent in muscle fibre characteristics compared with young
adults,110 possibly relating to the age-related remodeling of
motor units.111 Despite these issues, the data provided
sufficient resolution to disclose marked increases in muscle
fibre CSA and changes in muscle fibre proportions over the
entirety of the training intervention, as previously presented
(Figure 4 and Supporting Information, Figure S1).
In order to achieve reliable assessment of changes in mus-
cle mass, we thus had to take on a different approach. In-
stead of relying on muscle fibre CSA data alone, we
developed a combined muscle mass factor, in which change
scores from a collection of muscle mass-related outcome
measures were combined in a weighted manner (Supporting
Information, Table S4). This factor included data on muscle fi-
bre CSA, leg lean mass (DXA) and muscle thickness (m. rectus
femoris, m. vastus lateralis; ultrasound), all of which are
known to correlate.112–114 Careful investigation of the
computed muscle mass factor suggested that it increased
the biological value of muscle mass-related analyses (for
more information, see Supporting Information, Table S4). As
such, it changed markedly from baseline to post-RCT (9%,
P < 0.001, Supporting Information, Table S4). Following this
logic, combined factors were also computed for other core
outcome domains, including maximal muscle strength and
one-legged and whole-body endurance performance
(Supporting Information, Table S4).
Effects of vitamin D3 supplementation on
training-associated changes in maximal muscle
strength and lower-limb muscle mass
Participants in both vitamin D3 and placebo arms showed
increases for every measure of muscle strength and mass,
assessed from baseline to after finalization of the resistance
training intervention: 12–25% for upper- and lower body
1RM muscle strength, 6–11% for leg muscle torque, 7–26%
for muscle fibre CSA and muscle thickness and 1–3% for leg
lean mass (Figures 6 and 7). Unsurprisingly, after combining
these measures into weighted muscle strength and muscle
mass factors, similarly scaled increases were observed
(13% ± 8% and 9% ± 8%, respectively; Figures 6 and 7), which
was also the case for a calculated score of relative muscle
quality (Δmuscle strength factor/Δmuscle mass factor;
4% ± 10%, Figure 7).
Overall, vitamin D3 supplementation did not affect these
outcome measures compared with placebo in the partici-
pants, primarily evaluated as changes in muscle strength
and muscle mass factors (strength, Δ2.5% (95% CI, 1.0,
6.0), P = 0.194; mass, Δ0.4% (95% CI, 3.5, 4.3), P = 0.940,
Figures 6 and 7), and secondarily as changes in each of the
underlying outcome measures (i.e. seven measures of muscle
strength and three measures of muscle mass; Figures 6 and
7). This lack of a beneficial effect was also evident for changes
in relative muscle quality (Δ1.9% (95% CI, 3.0, 6.8),
P = 0.415; Figure 7). Vitamin D3 supplementation thus had
no main effect on training-associated changes in muscle func-
tionality or gross muscle biology. While this conclusion co-
heres with the few comparable studies assessing the effect
of combined vitamin D3 intake and resistance training,
40,42–44
it contrasts the conclusion drawn in the only available
meta-analysis on this subject, wherein vitamin D3 supplemen-
tation was associated with augmented increases in muscle
strength in older adults.41 Notably, among the selection of
ten specific outcome measures, two did not conform with
the main finding. Vitamin D3 was associated with beneficial
effects for changes in 1RM knee extension (Δ6.8% (95% CI,
1.3, 12.3), P = 0.016; Figure 6) and muscle thickness of
m. rectus femoris (Δ7.5% (95% CI, 1.8, 13.2), P = 0.011; Figure
7). For 1RM knee extension, the effect was interrelated
with the negative development seen from pre-RCT to
pre-introduction to training in the vitamin D3 arm
(Supporting Information, Figure S1). Indeed, when assessing
the effect of vitamin D3 on 1RM knee extension from pre-
to post-RCT (rather than from baseline at post-introduction
to training), no beneficial effect was observed compared with
placebo (Δ2% (95% CI, 12, 7), P = 0.628; Supporting Infor-
mation, Table S2). As for muscle thickness in m. rectus
femoris, we did not collect data pre-RCT and can thus not de-
duce if this variable followed the same pattern as 1RM knee
extension. The observed benefits of vitamin D3 supplementa-
tion for changes in m. rectus femoris thickness contrasts ob-
servations made for m. vastus lateralis thickness (Δ0.3%,
P = 0.838), and even oppose those made for lean mass of
the legs, which tended to increase less in the vitamin D3
arm compared with the placebo arm (Δ1.8%, P = 0.090).
So far, analyses have focused on the main effect of vitamin
D3 supplementation for training-induced development
of muscle strength and mass, and have thus neglected
potential interactions with other independent variables such
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as pre-RCT levels of 25(OH)D, health status (COPD vs. non-
COPD) or training modality (high-load, 10RM, vs. low-load,
30RM). The benefits of vitamin D3 supplementation were
expected to be more pronounced in participants with low
baseline levels of 25(OH)D (ClinicalTrials.gov Identifier:
NCT02598830). This hypothesis was based on observations
made in cohort studies, wherein subjects with levels <30–
50 nmol/L are more likely to show adverse muscle
phenotypes.21–23 To investigate this perspective, participants
in each supplementation arm were divided into quartiles
based on pre-RCT 25(OH)D levels in blood (Supporting
Information, Figure S3). This resulted in two lower quartiles,
one for the vitamin D3 arm (vitamin D3low, [25(OH)D]-
mean = 49.5 nmol/L, n = 8), and one for the placebo arm
(placebolow, [25(OH)D]mean = 47.4 nmol/L, n = 12) (Supporting
Information, Figure S3). At the onset of introduction to resis-
tance training, 25(OH)D levels in vitamin D3low had increased
to 103.3 nmol/L (range 76–138), with all participants being
classified as sufficient (>50 nmol/L),17 whereas 25(OH)D levels
in placebolow remained unchanged (45.5 nmol/L, range
22–71), with 9 out of 12 participants being classified as insuf-
ficient (<50 nmol/L). Within each of the pre-RCT 25(OH)D
quartiles, the effect of vitamin D3 and placebo supplementa-
tion on training-induced changes in muscle strength and mass
(using the combined factors) were assessed. With exception of
one quartile (muscle strength factor, quartile 3, P = 0.048;
Supporting Information, Figure S3), no beneficial effects of
vitamin D3 supplementation were observed in any quartile
(e.g. vitamin D3low vs. placebolow, muscle strength, Δ2.0%
(95% CI, 8.0, 3.9, P = 0.496) (Supporting Information,
Figure S3). Instead, in vitamin D3low, training-associated
changes in muscle mass were reduced compared with
placebolow (Δ6.5% (95% CI, 12.7, 0.27), P = 0.041;
Supporting Information, Figure S3), suggesting that vitamin
Figure 6 Effects of combined vitamin D3 supplementation and resistance training on maximal muscle strength in older adults. Changes in muscle
strength from baseline (after three weeks of introduction to resistance training) to post-RCT (A), and differences in changes between vitamin D3
and placebo arms (B). KE, one-legged knee extension; LP, one-legged leg press; CP, chest press; maximal torque measured using one-legged knee ex-
tension at three velocities; 60, 180, and 240° per second; #, significant difference between vitamin D3 and placebo arms; combined strength factor,
weighted combined strength factor of unilateral strength measures (one-repetition maximum in KE and LP, and KE torque at 60, 180, and 240° per
second). Alpha level at P < 0.05. Data are presented as means with 95% confidence intervals.
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D3 supplementation may even have compromised training ad-
aptations in subjects with low pre-RCT 25(OH)D levels. Adding
to this, participants in the entire spectre of quartiles
responded quite similarly to resistance training, irrespective
of supplementation arms, evident as no interaction between
25(OH)D quartiles/supplementation arm and changes in mus-
cle strength (P = 0.237) or muscle mass (P = 0.159). Arguably,
the statistical power of these analyses were not sufficiently
high to conclude on this perspective.
The impact of vitamin D3 supplementation for
training-associated changes in muscle strength and muscle
mass factors did not interact with health status (COPD
vs. non-COPD) or training modality (10RM vs. 30RM)
(Supporting Information, Table S2). However, it should be
noted that for selected specific outcome measures, interac-
tions were found with both of these independent variables
(summarized in Supporting Information, Table S2), including
an interaction between changes in type II-fibre CSA and
COPD/non-COPD, and between changes in 1RM knee exten-
sion/vastus lateralis thickness and 10RM/30RM. In addition
to these interaction analyses, we also investigated the
potential relation between the effects of vitamin D3
supplementation and baseline body fat proportions, as over-
weight and obese have been shown to have decreased
bioavailability of vitamin D due to deposition of 25(OH)D in
body fat compartments (while concomitantly showing
attenuated anabolic response to resistance exercise115).116
To this end, we performed quartile-based analyses, as previ-
ously described. These analyses did not reveal an effect of
baseline body fat proportions for changes in [25(OH)D] (fat
percentage, P = 0.432; BMI, P = 0.369) or muscle mass factor
(fat percentage, P = 0.355; BMI, P = 0.293) (Supporting
Information, Figure S4). However, it did have an effect on
changes in the muscle strength factor (fat percentage,
P = 0.016; BMI, P = 0.706), that is, in quartilehigh fat percentage,
vitamin D3 supplementation was associated with larger
increases in muscle strength compared with placebo (fat
percentage, Δ 5.8% (95% CI, 0.5, 11.0), P = 0.032; BMI,
Δ7.8% (95% CI, 2.5, 13.1), P = 0.005; Supporting Information,
Figure S4 and Table S2), suggesting beneficial effects of
vitamin D3 supplementations in subjects with high propor-
tions of body fat, opposing our initial expectations.
Figure 7 Effects of combined vitamin D3 supplementation and resistance training on lower-limb muscle mass in older adults. Changes in lower-limb
muscle mass from baseline (before introduction to resistance training) to post-RCT (A), and differences in changes between vitamin D3 and placebo
arms (B). CSA, cross-sectional area (also presented in Figure 4); RF, m. rectusfemoris; VL, m. vastus lateralis; LM per leg, leg lean mass per leg; #,
significant difference between vitamin D3 and placebo arms; combined muscle mass factor, weighted combined muscle mass factor including fibre
cross-sectional area (type I and type II), muscle thickness (RF and VL) and LM per leg; muscle quality, muscle strength factor/muscle mass factor. Alpha
level at P < 0.05. Data are presented as means with 95% confidence intervals.
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Effects of vitamin D3 supplementation on
training-associated changes in one-legged and
whole-body endurance performance
Participants in both vitamin D3 and placebo arms showed im-
provements in one-legged and whole-body endurance perfor-
mance over the course of the resistance training
intervention: 42–74% increases in one-legged muscular per-
formance (Figure 8), 7–9% increases in peak power output
(Wmax) in one- and two-legged cycling (Figure 8), 3–5% reduc-
tions in O2 costs of submaximal one-legged cycling
(Supporting Information, Table S2), and 6–10% increases in
functional performance (1-min sit-to-stand test and 6-min
step test, Figure 8). In accordance with this, marked increases
were observed in weighted one-legged and whole-body en-
durance performance factors (one-legged, vitamin D3
25% ± 19%, placebo 22% ± 11%; whole-body, vitamin D3
9% ± 8%, placebo 7% ± 6%; Figure 8). These effects cohere
well with previously observed benefits of resistance training
for endurance variables in older adults.117–119
Vitamin D3 supplementation had no effect for any of these
outcome measures compared with placebo, neither for
weighted endurance performance factors (one-legged, Δ2%
(95% CI, 5, 10), P = 0.773; two-legged, Δ2% (95% CI, 2,
6), P = 0.636; Figure 8), nor for any of the specific outcome
measures (Figure 8). For combined endurance factors, there
was no interaction between baseline 25(OH)D quartiles
and effects of vitamin D3 supplementation (one-legged,
P = 0.950; whole-body, P = 0.266; Supporting Information,
Figure S3 and Table S2), nor was there any interactions with
health status (one-legged, P = 0.747, whole-body, P = 0.129,
Supporting Information, Table S2) or training modality
(one-legged, P = 0.719, Supporting Information, Table S2).
Effects of vitamin D3 supplementation on
training-associated changes in muscle fibre
characteristics and transcriptomics
Participants in both vitamin D3 and placebo arms showed
marked changes in muscle fibre characteristics over the
course of the training intervention. These included decreased
type IIX muscle fibre proportions from 10% to 7% (Figure 9),
increased type IIA proportions from 26% to 29% (Figure 9),
Figure 8 Effects of combined vitamin D3 supplementation and resistance training on one-legged and whole-body endurance performance in older
adults. Changes in endurance performance from baseline (before introduction to resistance training) to post-RCT (A), and differences in changes
between vitamin D3 and placebo arms (B). 1KE, repetitions to failure in one-legged knee extension (50% of pre-intervention 1RM); CP, repetitions
to failure in chest press (50% of pre-intervention 1RM); Wmax, maximal power output; 6-min step test, maximal number of steps achieved during
6 min; Sit-to-stand, maximal number of sit-to-stands achieved during 1 min; combined 1-leg endurance performance factor, weighted combined
one-legged endurance factor including 1KE muscular performance and one-legged cycling Wmax; weighted combined whole-body endurance factor in-
cluding Wmax bicycling, 6-min step test and sit-to-stand test. Alpha level at P < 0.05. Data are presented as means with 95% confidence intervals.
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increased type IIA/IIX hybrid fibres abundances from 2.6% to
3.2% (Supporting Information, Table S2), and 25–48% in-
creases in myonuclei number per muscle fibre (Figure 9).
Changes in IIX and IIA proportions were verified using qPCR,
showing decreased levels of type IIX mRNA abundance and
increased levels of type IIA (Figure 9), calculated using the
gene family-profiling approach.76 These analyses also re-
vealed increased proportions of type I mRNA after the train-
ing intervention (Figure 9), potentially caused by increased
type I protein turnover. The observed changes in muscle
fibre-type characteristics corroborate well with previous
studies in older adults,120–122 although increased numbers
of myonuclei per muscle fibre are not consistently
reported.123 Vitamin D3 supplementation had no effect on
training-associated changes in muscle fibre proportions or
myonuclei content compared with placebo (Figure 9).
The training intervention resulted in 1.14- to 1.16-fold in-
creases in total RNA per unit muscle tissue weight (Figure
10), a proxy marker for ribosomal RNA content that has pre-
viously been associated with training-induced changes in
muscle growth and strength.67,124 Similar increases were
found for the mature ribosomal species 18 s (1.18-fold) and
28 s (1.16-fold), in addition to the 45 s pre-ribosomal rRNA
(1.19-fold) using qPCR (Figure 10). No changes were observed
for 5.8 s (1.07-fold, P = 0.722) or 5 s (1.06, P = 0.940) follow-
ing the entire training intervention. Notably, for analyses of
total RNA and ribosomal RNA, an additional time point were
included in main analyses, i.e. in muscle biopsies sampled af-
ter introduction to training (3.5 weeks, 7 sessions), as early
increases in total RNA seem to associate with long-term
chronic responses to training, making it a potential hallmark
of muscle plasticity.67 As expected, 3.5 weeks of training led
to marked increases in total RNA (1.10- to 1.21-fold) and
expression of all ribosomal RNA species (1.13- to 1.27-fold)
(Figure 10). Whereas these changes corroborates quite well
with changes observed in healthy, young subjects,67 although
with a notable reduction in the relative increase, they
contradict previous observations of no resistance training-
associated increases in total RNA per unit muscle tissue
weight in older subjects.125 Vitamin D3 supplementation
had no effect on training-associated changes in total RNA or
rRNA expression compared with placebo.
The training intervention led to marked changes in muscle
mRNA transcriptome profiles in the two supplementation
arms combined, with 499 genes being differentially
expressed (DE) after 3.5 weeks of resistance training
Figure 9 Effects of combined vitamin D3 supplementation and resistance training on muscle fibre type proportions and myonuclei per fibre in m.
vastus lateralis of older adults. Muscle fibre type proportions (A–F) at baseline (before introduction to resistance training) and post-RCT measured
using immunohistochemistry (A–C) and qPCR (gene family profiling (GeneFam)-normalized myosin heavy chain mRNA expression, (D–F), and changes
in myonuclei count per type I and type II fibre from baseline to post-RCT (G). Significant changes were observed for fibre type IIA and IIX using both
methods (significant increase and decrease, respectively; P< 0.05). For fibre type I, an increased expression was present using qPCR (P< 0.05), but no
change was observed for immunohistochemistry (P = 0.322). P-values denotes the statistical difference between the supplementation arms. RT, resis-
tance training. Data are presented as means with 95% confidence intervals.
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(post-intro RT; 436 genes ↑, 63 genes ↓, Figure 11A) and
312 genes being DE after 13 weeks of resistance training
(post-RCT; 255 genes ↑, 57 genes ↓) (Figure 11A,B). VDR
was expressed, but unaffected by combined vitamin D3
supplementation and resistance training, contradicting
previous observations of a positive association between
supplementation-induced improvements in 25(OH)D
status and leukocyte,126 myoblast/myotube127 and skeletal
muscle128 VDR expression. GO enrichment analyses revealed
increased expression of gene sets associated with extracellu-
lar matrix, blood vessel morphogenesis and leukocyte migra-
tion at both 3.5 and 13 weeks (Figure 11C, Supporting
Information, Table S8), as well as increased expression of
the inflammatory response gene set at 3.5 weeks (Supporting
Information, Table S8). Conversely, decreased expression was
observed for gene sets involved in ribosomal functions at
both 3.5 and 13 weeks (Figure 11C). This could be interpreted
as contradicting the likely important role of de novo
ribosomal biogenesis for training-associated muscular
adaptations.67,124 Notably, as these analyses were performed
using traditional library size-based normalization, which
basically provided target gene expression relative to the
expression of all other genes.129 In an alternative set of
transcriptome analyses, which rather included normalization
that corrected for muscle sample weight and thus provided
gene expression analyses per sample size (tissue-offset
normalization),129 the negative effects of resistance training
on ribosomal gene expression was not evident (data not
shown). This was the only major difference between library
size and tissue-offset normalization in the present study
setting.
Vitamin D3 supplementation had no effect on
training-associated changes in gene expression, neither at
3.5 weeks (Figure 11D) nor at 13 weeks (Figure 11E), suggest-
ing that no single gene was differentially affected by
combined vitamin D3 supplementation and resistance
training and resistance training-only. In contrast to this,
enrichment analyses showed traces of vitamin D3-sensitive
changes in expression at both 3.5 and 13 weeks of resistance
training (Figure 11F and Supporting Information, Tables
S9–S10). After 3.5 weeks of training, there was differential
expression of gene sets involved in cell junctions, blood
vessel morphogenesis and muscle cell differentiation. These
initial responses to resistance training should be interpreted
with caution, as they were only evident in one of the two
analyses (GSEA or rank-based analyses; Figure 11F and
Supporting Information, Tables S9–S10). After 13 weeks
of resistance training, the vitamin D3 arm showed
increased expression of gene sets involved in endothelial
proliferation and blood vessel morphogenesis compared with
placebo (Figure 11F). This agrees with the previously
observed positive relationship between 25(OH)D-status and
endothelial function, potentially interacting through the
endothelium-derived vasodilator, nitric oxide.100 Indeed, this
coheres well with a recent study, which showed favorable ef-
fects of combined vitamin D3 supplementation and resistance
Figure 10 Effects of combined vitamin D3 supplementation and resistance training on total RNA abundances and rRNA expression inm. vastus lateralis
of older adults. Total RNA (A), 18 s rRNA (B), 28 s rRNA (C), 5.8 s rRNA (D), 5 s rRNA (E), and 45 s pre-rRNA (F) abundances at baseline (before intro-
duction to resistance training) and post-RCT. Significant increases from baseline–post-introduction to resistance training were present for all variables
(P < 0.05). From baseline–post-RCT significant increases were present for all variables (P < 0.05), with the exception of 5.8 s rRNA (P = 0.722) and 5 s
rRNA (P = 0.940). RT, resistance training. P-values denotes the statistical difference between the supplementation arms. Alpha level at P < 0.05. Data
are presented relative to amounts of tissue weight. Data are presented as means with 95% confidence intervals.
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Figure 11 Effects of 3.5/13 weeks of resistance training-only (A–C) and 3.5/13 weeks of combined vitamin D3 supplementation and resistance training
(D–G) on mRNA transcriptome profiles in m. vastus lateralis of older adults. Resistance training-only led to robust changes in gene expression at both
3.5 weeks (A; post-intro resistance training – pre-intro resistance training) and 13 weeks (B; post-RCT – pre-intro resistance training), including in-
creased expression of collagen type IV α1 and α2 genes (COL4A1 and COL4A2, respectively) and decreased expression of the myosin heavy chain
IIX gene (MYH1). The three most enriched gene sets with increased and decreased expression, in addition to the ‘blood vessel morphogenesis’ gene
set are shown in C (light blue, 3.5 weeks; dark blue, 13 weeks; according to the GSEA enrichment score). Combined vitamin D3 supplementation and
resistance training did not lead to differential changes in expression for a singular gene compared with placebo at neither 3.5 weeks (D; Δ, post-
introduction to resistance training - pre-introduction to resistance training) nor 13 weeks of resistance training (E; Δ, post-RCT - pre-introduction to
resistance training; orange dots/genes denotes leading edge genes from the ‘blood vessel morphogenesis’ GO gene set, that is, the most highly
enriched gene set between supplementation arms after 13 weeks of resistance training). GO enrichment analyses of differentially regulated gene sets
between the vitamin D3 and the placebo arms following 3.5 weeks (left panel, F) and 13 weeks of resistance training (right panel, F; positive/negative
GSEA-normalized enrichment scores indicates higher/lower expression of gene sets in the vitamin D3 arm compared with the placebo arm). (G) Time-
line for the 10 most affected genes between vitamin D3 and placebo arms belonging to the ‘blood vessel morphogenesis’ GO gene set. RT, resistance
training; Consensus, when both the non-directional rank-based enrichment test and the directional gene-set enrichment analysis (GSEA) turned out
significant. In Figure 11C,F, circle sizes of gene sets are relative to P-values, i.e. larger circles indicate lower P-values (see Supporting Information,
Tables S5–S10 for exact P-values).
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training on flow-mediated dilation of blood vessels and blood
pressure in postmenopausal women.130 Unfortunately, endo-
thelial function was not assessed in the current study.
Effects of vitamin D3 on hormones in blood and
health-related outcome measures
In general, the intervention was associated with beneficial
changes for several health-related variables, including
reduced levels of lipids (triglycerides and low-density lipopro-
tein/LDL), reduced levels of fat mass (total and visceral fat)
and improved self-reported health (Supporting Information,
Table S11). Conversely, a small but undesirable decrease
was observed in lung capacity, measured as forced
ventilatory capacity (FVC) (Supporting Information, Table
S2). The intervention was not associated with changes in
whole-body bone mineral density or changes in serum levels
of hormones, except for decreased levels of parathyroid
hormone (Supporting Information, Table S11), as previously
presented. For most of the health variables, there was no ef-
fect of vitamin D3 supplementation (Supporting Information,
Tables S2 and S11), with exception of cortisol levels in blood,
which increased more in the vitamin D3 arm (Table S11), and
lung function measured as FEV1/FVC-ratios, which declined in
subjects with COPD in the vitamin D3 arm (Supporting
Information, Table S2).
Sarcopenia
The intervention proved effective for treating age-related loss
in muscle mass, leading to 1.4% increases in total lean body
mass (P < 0.001) (Supporting Information, Table S11). This
reduced the number of participants that could be defined
as sarcopenic from 16% (11 subjects) to 12% (8 subjects),
with sarcopenia being defined as appendicular lean mass
(kg)/m2 greater than two standard deviations below the
sex-specific means of young adults.61 Speculatively, the
increase in total lean mass was supported by increased levels
of serum creatinine in both supplementation arms (+6%;
Supporting Information, Table S11). Although serum creati-
nine is generally used for evaluation of renal function,131
creatinine production and levels also increases with increases
in total muscle mass.131,132
Steroid hormones
Vitamin D3 supplementation did not affect levels of anabolic
steroid hormones such as testosterone. This was in discor-
dance with our initial hypothesis, as we presumed a positive
association between vitamin D levels (measured as 25(OH)D)
and testosterone levels, based on previous observations from
vitamin D3 supplementation studies
52 and cohort studies.133
Despite this, our finding is in line with several other vitamin
D supplementation studies, which has reported no effect
on testosterone in blood.134,135 Conversely, vitamin D3
supplementation seemed to affect serum cortisol levels com-
pared with placebo (Δ48 nmol/L, P = 0.038; Supporting Infor-
mation, Table S11), although no main effect of time was
observed (i.e. the observed increase in the vitamin D3 arm
was not statistically significant, P = 0.374) and there was no
statistical difference between supplementation arms at the
end of the intervention (P = 0.053).
Lung function
The small 1.95% reduction in FVC seen after the 28 week
long RCT (P = 0.006; Supporting Information, Table S2) was
surprising, as exercise is generally accepted to be beneficial
for lung functionality, including resistance training.136,137
Notably, other measures of lung function, such as forced
ventilatory volume in one second (FEV1 and predicted FEV1)
and FEV1/FVC, were not affected by the intervention
(Supporting Information, Table S2).
The negative effects of vitamin D3 on lung function, mea-
sured as FEV1/FVC (Δ2.9% points, P = 0.012; Supporting
Information, Table S2), were also surprising. This effect
showed a clear interaction with health status, and as such
was only evident in COPD patients in the vitamin D3 arm,
which showed Δ8.4% reductions compared with placebo
(Supporting Information, Table S2). This subgroup analysis
was however clearly weakened by the small sample size
(COPD, n = 9 vs. n = 11, vitamin D3 vs. placebo). The negative
effect of vitamin D3 on FEV1/FVC did not interact with
pre-RCT levels of FEV1/FVC, but surprisingly, in another sub-
group-analysis, the pre-RCT 25(OH)D vitamin D3low quartile
was associated with larger decrement in FEV1/FVC than
placebolow (Δ5.4% points, P = 0.009; data not shown). This
observation is difficult to explain, as it indirectly opposes the
notion that vitamin D deficiency leads to impaired lung
functions.138 More research is clearly needed to elucidate
on the consequences of resistance training and vitamin D3
supplementation for lung functionality.
Adverse effects of the intervention
Overall, neither vitamin D3 supplementation nor resistance
training was associated with adverse effects or events during
the intervention, with potential exception of certain aspects
of lung function, as previously discussed, and iron biology
(see Supporting Information, Table S11).
Primarily, a health survey was administered to the partici-
pants on a weekly basis. This included rating of 11 potential
discomforts relating to digestion problems, sleep problems,
issues with the urinary system, issues with the vestibular
system and dermal irritations (Supporting Information, Table
S2). No effect of vitamin D3 supplementation was found for
any of these variables. In the health survey, participants were
also asked to rate their experienced health on a point-scale
from 0–10. This self-reported conception of health
improved from 6.3 ± 1.6 to 7.1 ± 1.6 (P < 0.001, Supporting
Information, Table S2), with no difference between
Vitamin D and effects of resistance training in older adults 621
Journal of Cachexia, Sarcopenia and Muscle 2021; 12: 599–628
DOI: 10.1002/jcsm.12688
supplementation arms (P = 0.433, Supporting Information,
Table S11).
The intervention was not associated with
training-associated injuries, with only five participants (6%)
reporting discomforts with training towards the end of the in-
tervention and only four participants (5%) withdrawing from
study during the resistance training intervention, neither of
which were due to injuries associated with the training. As
such, serum levels of markers of muscle tissue damage
(creatine kinase and aspartate aminotransferase) even
decreased during the intervention, with no effects of vitamin
D3 supplementation (Supporting Information, Table S11).
Supervised resistance training can safely be advocated for
both healthy older adults and persons with COPD.
Concluding remarks
The study was conducted as a double-blinded RCT, address-
ing the effects of 12 weeks of vitamin D3 supplementation
only (i.e. two weeks of 10 000 IU/day, followed by ten weeks
of 2000 IU/day), and 13 weeks of combined vitamin D3
(2000 IU/day) and resistance training on functional measures,
health markers and muscle biology in a mixed population of
older adults. Vitamin D3 supplementation is often hailed as
an ergogenic aid for optimizing the outcome of resistance
training, and is recommended for a variety of human
populations, ranging from healthy subjects to athletes and
chronically diseased subjects.7,20 Vitamin D is thus presumed
to play an important role in training-associated muscle plas-
ticity. Despite this, its importance for humans remains largely
elusive, with current knowledge stemming predominantly
from animal research,55 and the few existing human studies
providing limited, uncertain and contradicting results.41–44 In-
deed, the present data do not support a role for vitamin D in
training-associated muscle plasticity and functionality, at
least not in older adults (with and without moderate COPD)
with suboptimal to adequate baseline levels of 25(OH)D.
More precisely, vitamin D3 supplementation had no effect
on core outcome domains such as changes in muscle
strength, muscle mass, endurance performance and general
muscle cell characteristics, and its effects on the muscle
transcriptome was largely limited to gene sets relating to
endothelial and cardiovascular functions. The validity of this
insight is fortified by the thorough methodological and
analytical approach. This included accounting for previous
methodological issues such as a lack of a pre-training supple-
mentation period, low vitamin D dosages, and neglecting to
standardize test/training routines such as supervision of
training sessions, test–retest analyses of functional and
biological outcome measures, familiarization to training and
a low reproducibility of singular outcome measures. The ana-
lytical approach also accounted for the potential confounding
effects of the heterogeneity of the study population, as no
interaction was found between effects of vitamin D3
supplementation and disease status (healthy vs. COPD), or
differences in pre-RCT vitamin D status, as all [25(OH)D]-
baseline quartiles responded in similar manners.
Despite our substantial efforts to strengthen the ecological
value of the data set, there are aspects of vitamin D biology
that remain unresolved, and that may have affected the con-
clusions and outcomes of the study. First, in skeletal muscle,
adequate vitamin D signaling may occur at 25(OH)D levels
lower than the defined cutoff (insufficient, <50 nmol/L).27
Speculatively, all participants in the placebo arm may thus
have been vitamin D-sufficient at the onset of resistance
training, leaving our quartile-based analyses with limited bio-
logical value. Indeed, studies have suggested that vitamin D
insufficiency will affect human muscle in an adverse manner
only at concentrations <30 nmol/L.139 Second, although se-
rum 25(OH)D level is widely regarded as an adequate mea-
sure of vitamin D status,63 it may be a poor proxy marker
for vitamin D biology, as it largely fails to reflect 1,25(OH)2D
levels, the metabolically active form of vitamin D.140 In line
with this, in the present study, [25(OH)D] was not correlated
with [1,25(OH)2D] at baseline (data not shown) and was not
increased by long-term vitamin D3 supplementation (at
weeks 13 and 29). Such decoupling of 25(OH)D and 1,25
(OH)2D levels have several potential explanations. These in-
clude feedback-mediated regulation of vitamin D biology,
which is largely affected by PTH levels,141 as well as impaired
25(OH)D → 1,25(OH)2D conversion in individuals with patho-
physiological indications such as renal dysfunction.142 The lat-
ter is unlikely to explain the lack of increases in [1,25(OH)2D]
in the present study, as only two participants were indicated
with renal dysfunction (estimated based on levels of
creatinine in serum; Table 1). Rather, the initial two weeks
of high-dosage vitamin D3 supplementation did lead to
marked increases in [1,25(OH)2D], emphasizing that
supplementation is indeed capable of increasing levels of
metabolically active vitamin D, at least at high doses and
within a short time frame. At weeks 13 and 29 were the
PTH levels suppressed for both supplementation arms
compared with pre-RCT levels. This was possibly related to
the calcium supplement, and may have contributed to the
unaltered 1,25(OH)2D levels at these time points. Third,
muscle cells may themselves possess the apparatus to
convert 25(OH)D into 1,25(OH)2D, as they express the
25-Hydroxyvitamin D 1-alpha-hydroxylase (CYP27B1) protein.
Indeed, in in vitro experiments on murine myoblast and
myotubes, 25(OH)D and 1,25(OH)2D treatment seem to lead
to similar increases in the expression of vitamin D markers
such as VDR, suggesting that peripheral regulation of vitamin
D biology is a biological opportunity.127 Fourth, while 25(OH)
D was assessed as [25(OH)D]total in the present study, levels
of unbound 25(OH)D (i.e. not bound to vitamin D binding
protein or albumin; ~0.03%) may represent a more accurate
measure of vitamin D status in a clinical setting.143 Indeed,
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in mice lacking vitamin D binding protein, and therefore
displaying very low [25(OH)D]total (~8 nmol/L), no signs of vi-
tamin D deficiency are seen unless they are put on a vitamin
D deficient diet.144 Fifth, in the present study, the resistance
training intervention lasted for only 13 weeks. Speculatively,
this may have been too short for vitamin D3 supplementation
to manifest its potential benefits for muscle plasticity, despite
the presence of a 12-week lead-in supplementation period.
Arguably, however, if vitamin D status and signaling is indeed
important of muscle biological adaptations to training, even
shorter interventions should lead to detectable changes in
muscle biology, such as its transcriptome. This was not
observed, neither in general, nor for specific vitamin
D-responsive genes such as VDR.128 Sixth, the study protocol
was unavoidably associated with large interindividual
variation in responses. This variation may have been related
to vitamin D3 supplementation per se, resistance training
per se or to a combination of both, and may have affected
groupwise comparisons. More research is clearly needed to
elucidate on these perspectives.
Despite these uncertainties, it seems clear that vitamin D3
supplementation did not affect muscle biological characteris-
tics in the present study, particularly those measured using
RNA-seq. Indeed, in our transcriptome analyses, not a single
gene was found to be vitamin D3-sensitive after a period of
resistance training, which is surprising given the accepted
dogma that vitamin D primarily acts as a transcriptional
regulator,55 and that the VDR was rather highly expressed
in the data set, although it did not change with vitamin D3
supplementation. Moreover, gene sets that were identified
as vitamin D3-sensitive in gene enrichment analyses were
largely associated with vascular function rather than muscle
cell biology.
Despite the general lack of effects of vitamin D3 supple-
mentation on muscle mass and phenotype (primary objec-
tives of the study), as well as the lack of effects on other
muscle functional and biological traits, the data set
contained a couple of interesting observations. First, in
the muscle transcriptome data, the effects of vitamin D3
supplementation per se on expression of mitochondrial
genes and the effects of combined vitamin D3 supplemen-
tation and resistance training on biomarkers of endothelial
and vascular biology calls for further study. Arguably, these
biological features would be more decisive for adaptations
to endurance-like training, posing the intriguing possibility
that vitamin D3 supplementation may be beneficial for
the outcome of such training. Second, in participants with
high baseline fat proportions/high BMI, vitamin D3 supple-
mentation led to increased training-associated changes in
muscle strength. In these participants, the bioavailability
of vitamin D may have been compromised by the high fat
content (in the placebo arm, although they did not exhibit
lowered 25(OH)D levels), corroborating with previous ob-
servation of interactions between vitamin D biology and
fat mass.116 While this may indicate that vitamin D exerts
direct effects on muscle biology, as muscle strength is
predominately defined by muscle mass,145 this still seems
unlikely as no such vitamin D3-effect was seen for other
muscle-specific outcome measures (e.g. muscle mass and
phenotype). The causality may thus involve other physio-
logical adaptations such as motoneuron function,146 which
has indeed been suggested to be affected by vitamin D
supplementation in rodents.147
In retrospect, the pre-identified primary objectives of the
current study were not ideal (i.e. the effects of vitamin D3
supplementation on muscle fibre CSA and proportions). The
underlying rationale behind this choice was to investigate
the effects of vitamin D3 supplementation on a set of unbi-
ased biological variables (not prone to test–retest fluctua-
tions), adhering to the existing notion that vitamin D may
affect muscle fibre size and fibre type proportions (e.g.
elucidated in the review from Ceglia, 2009148). This clearly
underestimating the reliability issues associated with
histological measures, which were indeed evident in the data
set (Supporting Information, Figure S2). Importantly, vitamin
D3 supplementation was not associated with beneficial
effects for any of the investigated primary or secondary
outcome measures, hence leaving the overall conclusion as
unambiguous.
In conclusion, in older adults with or without COPD,
vitamin D3 supplementation efficiently improved vitamin
D-status without any adverse effects, but did not lead to ben-
eficial effects in resistance training-associated changes in
muscle function or characteristics. This rejects the notion that
vitamin D3 supplementation is necessary to obtain adequate
muscular responses to resistance training in the general older
population. Secondary analyses revealed positive effects of
vitamin D3 supplementation for participants with high
proportions of fat mass and for gene sets involved in vascular
functions, advocating further research to elucidate on these
specific biological characteristics. Finally, the training
programme was well-tolerated and associated with pro-
nounced effects for a variety of health variables, emphasizing
the potency of resistance training for relieving sarcopenia
and maintaining functional capacity in older adults with and
without COPD.
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